143 related articles for article (PubMed ID: 37034762)
1. Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer.
Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
medRxiv; 2023 Mar; ():. PubMed ID: 37034762
[TBL] [Abstract][Full Text] [Related]
2. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.
Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and survival in patients with early-onset pancreatic cancer.
Saadat LV; Chou JF; Gonen M; Soares KC; Kingham TP; Varghese AM; Jarnagin WR; D'Angelica MI; Drebin JA; O'Reilly EM; Wei AC
Cancer; 2021 Oct; 127(19):3566-3578. PubMed ID: 34228820
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
[TBL] [Abstract][Full Text] [Related]
7. Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing.
He Y; Huang W; Tang Y; Li Y; Peng X; Li J; Wu J; You N; Li L; Liu C; Zheng L; Huang X
Front Oncol; 2023; 13():1167144. PubMed ID: 37313463
[TBL] [Abstract][Full Text] [Related]
8. The burden of young-onset pancreatic cancer and its risk factors from 1990 to 2019: A systematic analysis of the global burden of disease study 2019.
Dahia SS; Konduru L; Pandol SJ; Barreto SG
Pancreatology; 2024 Feb; 24(1):119-129. PubMed ID: 38151359
[TBL] [Abstract][Full Text] [Related]
9. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
12. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract][Full Text] [Related]
13. Clinical and genomic characterisation of early-onset pancreatic cancer.
Castet F; Fabregat-Franco C; Castillo G; Navarro V; Sierra A; Acosta DA; López-Valbuena D; Dienstmann R; Tabernero J; Vivancos A; Tian TV; Macarulla T
Eur J Cancer; 2023 Nov; 194():113338. PubMed ID: 37793216
[TBL] [Abstract][Full Text] [Related]
14. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer.
Hong JY; Cho HJ; Kim ST; Park YS; Shin SH; Han IW; Lee J; Heo JS; Park JO
Ther Adv Med Oncol; 2021; 13():17588359211038478. PubMed ID: 34471425
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
Luchini C; Brosens LAA; Wood LD; Chatterjee D; Shin JI; Sciammarella C; Fiadone G; Malleo G; Salvia R; Kryklyva V; Piredda ML; Cheng L; Lawlor RT; Adsay V; Scarpa A
Gut; 2021 Jan; 70(1):148-156. PubMed ID: 32350089
[TBL] [Abstract][Full Text] [Related]
19. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma.
Desai A; Xiao AH; Choi D; Toruner MD; Walden D; Halfdanarson TR; Alberts S; McWilliams RR; Mahipal A; Ahn D; Babiker H; Stybayeva G; Revzin A; Kizilbash S; Adjei A; Bekaii-Saab T; Mansfield AS; Carr RM; Ma WW
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
